Salvage temozolomide for prior temozolomide responders

Cancer

Volumn 104, Issue 11, 2005, Pages 2473-2476

  Franceschi, Enrico ^a   Omuro, Antonio M P ^b   Lassman, Andrew B ^b   Demopoulos, Alexis ^b   Nolan, Craig ^b   Abrey, Lauren E ^b  

^a BELLARIA HOSPITAL   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brain tumor; Chemotherapy; Glioblastoma; Glioma; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; BLOOD TOXICITY; BRAIN RADIOGRAPHY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; LEUKEMIA; MALE; MYELODYSPLASIA; NEUTROPENIA; OLIGODENDROGLIOMA; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 28044450847     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21564     Document Type: Review

References (10)

1. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
2. Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol. 2001;19:2449-2455.
3. Brandes AA, Ermani M, Basso U, et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol. 2001;12:255-257.
4. Stupp R, Van Den Bent MJ, Weller M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352987-996.
5. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14:1715-1721.
6. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003;212525-2528.
7. Sanson M, Cartalat-Carel S, Taillibert S, et al. Initial chemotherapy in gliomatosis cerebri. Neurology. 2004;63:270-275.
8. Macdonald DR, Cascino TL, Schold SC Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
9. Herzog TJ, Holloway RW, Stuart GC. Workshop: options for therapy in ovarian cancer. Gynecol Oncol. 2003;90(Suppl 1):S45-S50.
10. Bodell WJ, Gaikwad NW, Miller D, Berger MS. Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors. Cancer Epidemiol Biomarkers Prev. 2003;12:545-551.